Detailed Narrative
Q4 & FY25 Financial Performance Overview
Shree Ganesh Remedies reported a challenging Q4 FY25, with revenue from operations declining 35% YoY to ₹24.43 crores, primarily due to a slowdown in the European region and a 25-30% reduction in domestic product realizations. EBITDA for the quarter fell 42% YoY to ₹9.88 crores, leading to a 492 bps contraction in EBITDA margin to 40.4%. Profit After Tax (PAT) also saw a significant 48% YoY drop to ₹6.60 crores, impacted by higher depreciation and finance costs from newly commissioned manufacturing block 8. For the full FY25, revenue was ₹108.60 crores (down 14% YoY), while EBITDA decreased 6% to ₹39.21 crores, though the EBITDA margin improved by 290 bps to 36% due to operational efficiencies and increased CRAMS contribution. Full-year PAT was ₹23.10 crores, an 18% decline YoY.
Strategic Focus on CRAMS and New Project Development
The CRAMS division remains a cornerstone of the company's growth strategy, contributing approximately 15-20% of FY25 revenue. A significant development is the signing of an MOU with a leading Japanese client for a Specialty Chemical project, with commercial supplies anticipated to commence later this year, targeting a peak annual revenue of 30+ crores. In the agrochemical sector, the company secured source status for a key product destined for the European market, with commercialization expected in H2 calendar year 2026, aiming for 30-35+ crores peak revenue. These new CRAMS projects are characterized by higher complexity, involving 4-8 steps compared to previous 2-3 step projects, and are chemistry-driven and customer-specific.
Capacity Expansion and R&D Intensification
Shree Ganesh Remedies is actively expanding its capabilities and R&D efforts. A new pilot plant is under construction and is expected to be operational in the current financial year (FY26), which will accelerate the development and scale-up of new CRAMS projects. The company has also commenced the development of common infrastructures and utilities at its Dahej site, funded through internal accruals, to support future large-scale CRAMS projects. Manufacturing Block 8 was commissioned in Q1 FY25, and construction for the next manufacturing block is ongoing. The projected CapEx for FY26 is approximately ₹15 crores, demonstrating continued investment in growth.
FY26 Outlook: Consolidation and Margin Normalization
Management anticipates FY26 to be a year of consolidation and capacity building. Short-term margin pressures are expected to persist due to contract repricing and ramp-up costs associated with new capacities. EBITDA margins are projected to normalize to a range of 24-26% for FY26. Despite these pressures, the company expects moderate top-line growth in FY26 and aims for a long-term vision of doubling revenue with a 20-25% CAGR over the next 3-4 years, driven by the commercialization of new CRAMS and agro projects.
Asset Utilization and Sustainability Initiatives
The company's net asset turnover for property, plant, and machinery was 3x in FY24, but currently stands at 1.5-2x, reflecting the impact of recent capacity additions not yet fully utilized. The target is to achieve a 2x asset turnover going forward⏳. In line with its commitment to sustainable manufacturing, Shree Ganesh Remedies commissioned a 2.5 MW solar power park, which is expected to contribute up to 70% of its electricity from renewable sources, reducing its environmental footprint.